Kingston Health Sciences Centre has launched a specialized treatment program for sickle cell disease at Kingston General Hospital. The initiative provides local access to red cell exchange therapy, a critical procedure previously unavailable in the region.
Sickle cell disease is an inherited disorder causing misshapen red blood cells that trigger severe pain and multi-organ damage. Ontario Health estimates the condition affects approximately 3,500 people province-wide, with demographic shifts driving increased case numbers in Kingston.
Dr. Natasha Satkunam, a hematologist at KGH, confirmed the new capability ends mandatory patient transfers to Toronto or Ottawa. Chronic patients requiring monthly treatments can now receive care locally, significantly reducing logistical burdens for those managing this complex condition.
Lanre Tunji-Ajayi, CEO of the Sickle Cell Awareness Group of Ontario, emphasized the systemic nature of the disorder. He noted it impacts vital organs including the heart, lungs, and kidneys, potentially leading to premature death without proper management.
While gene therapy research continues, current options remain costly and limited in availability. Health officials stress that education and genetic screening are essential, as carriers often remain asymptomatic until having children diagnosed with the disease.